A Phase III Randomized Study of Cetuximab (Erbitux, C225) and Best Supportive Care Versus Best Supportive Care in Patients With Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Positive Colorectal Carcinoma

Trial Profile

A Phase III Randomized Study of Cetuximab (Erbitux, C225) and Best Supportive Care Versus Best Supportive Care in Patients With Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Positive Colorectal Carcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Oct 2016 Results (n=570) analysing derived neutrophil to lymphocyte ratio (dNLR) as a prognostic biomarker for predicting efficacy in NCT00640471 and NCT00079066 studies presented at the 41st European Society for Medical Oncology Congress
    • 05 Aug 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12606000112561).
    • 07 Jun 2011 Results of an analysis evaluating tumour size as a measure of response (n=358) presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top